Coping with Anxiety: Could One Dose of LSD Change Treatment?

What if severe anxiety could someday be treated with a single, medically supervised dose of LSD rather than a pill taken every day? New Phase 3 research suggests that possibility may be getting closer to reality. For people coping with anxiety, the findings are provocative: one 100-microgram dose of LSD produced measurable improvement that persisted for at least 12 weeks. That may seem too good to be true. Many psychiatrists, psychologists, clinical social workers and patients will find such research results challenging.

We Live in Challenging Times

It is easy to understand why so many people are suffering from anxiety. The headlines are designed to arouse our fears. It’s hard to miss stories about shootings, infections, war and the economy. Pundits have created a lot of polarization. If you were to poll your friends, neighbors and family members, chances are good that some of them would be suffering from anxiety and others might be dealing with depression.

Worrying about money is another common source of stress that causes anxiety. For people with extreme anxiety, called generalized anxiety disorder (GAD), there is new evidence of benefit from an unusual treatment–LSD.

Coping with Anxiety With LSD? Really?

LSD, or lysergic acid diethylamide, has been one of the most controversial drugs in America for more than half a century. That makes the newest research especially astonishing.

On September 14, 2026, Definium Therapeutics announced results from its Phase 3 Panorama trial of DT120, an orally disintegrating pharmaceutical formulation of LSD, also called lysergide. The study included 245 people with generalized anxiety disorder. Participants received a single dose of 100 micrograms of DT120, a lower 50-microgram dose or placebo.

Twelve weeks after that one dose, people receiving 100 micrograms had experienced an average 9.8-point reduction on the Hamilton Anxiety Rating Scale (HAM-A). Those receiving placebo improved by 4.7 points.

That produced a placebo-adjusted difference of 5.1 points.

The company reported that the difference was highly statistically significant. Improvement was detectable as early as the second day after treatment and persisted through the 12-week primary study period.

The results are striking for another reason: patients weren’t taking a pill every morning for those 12 weeks.

This is not yet an FDA-approved treatment. These are also newly announced Phase 3 results rather than a fully published peer-reviewed report. Definium says it plans to meet with the FDA during the fourth quarter of 2026 and anticipates filing a New Drug Application (NDA) during the first half of 2027.

How Does LSD Compare With Standard Anxiety Medicines?

If one dose of LSD can reduce anxiety for 12 weeks, an obvious question follows: How does that stack up against conventional anti-anxiety medicines?

There is an important caveat. Definium did not compare DT120 head-to-head with alprazolam (Xanax), diazepam (Valium), escitalopram (Lexapro), duloxetine (Cymbalta) or another established anxiety medicine. The comparison was with placebo. So we cannot say that LSD has been proven better than standard treatments.

Nevertheless, the magnitude of the response is intriguing. In the Phase 3 Panorama trial, one 100-microgram dose of DT120 produced a 5.1-point greater improvement than placebo on the Hamilton Anxiety Rating Scale (HAM-A) after 12 weeks. The standardized effect size was 0.64.

How unusual is that?

A meta-analysis of 56 randomized trials involving more than 12,000 people with generalized anxiety disorder found average placebo-controlled effect sizes of approximately:

• 0.33 for SSRI antidepressants
• 0.34 to 0.36 for SNRI antidepressants
• 0.50 for benzodiazepines

You can read that analysis in Expert Opinion on Pharmacotherapy, June 2018.

Another large analysis compared numerous medications used to treat generalized anxiety disorder (Lancet, Feb. 23, 2019). Commonly prescribed drugs generally improved HAM-A scores by roughly 2.5 to 3 points more than placebo.

For example, the placebo-adjusted improvements were approximately:

• 2.45 points for escitalopram
• 2.69 points for venlafaxine
• 2.79 points for pregabalin
• 3.13 points for duloxetine

Against that background, the 5.1-point placebo-adjusted improvement with DT120 certainly gets our attention.

But these are comparisons across different clinical trials conducted at different times with different patients. Researchers would need a direct head-to-head trial before concluding that LSD is more effective than conventional treatment.

The Bigger Difference May Be How Often You Take It

For us, the most remarkable part of this research may not be the numerical difference. It is the dosing strategy. People taking an SSRI, SNRI or benzodiazepine generally swallow medication every day. Treatment may continue for months or years. We frequently hear from people who have been on anti-anxiety agents for years or decades.

Participants in the DT120 trial received one dose. They spent roughly six to eight hours under supervision while the acute psychedelic effects wore off. Then they went home.

Three months later, the treatment group was still doing significantly better than the placebo group. That represents a fundamentally different approach to coping with anxiety. Instead of maintaining an effect by keeping a drug in the body every day, researchers are investigating whether one intense, carefully supervised treatment might trigger changes that persist long after the drug itself has disappeared from the body.

That does not mean one treatment will necessarily last forever. The longer portion of the Panorama study allows some participants to receive additional doses if their symptoms return.

And it does not suggest that LSD is free of complications. Nearly 95 percent of participants receiving the 100-microgram dose reported some type of treatment-emergent adverse event, most often altered perceptions, nausea or headache. Patients were monitored closely during the psychedelic experience.

Nevertheless, the idea that a person with chronic anxiety might receive treatment once and experience improvement for weeks or months is radically different from the way most psychiatric drugs are currently prescribed. And that may ultimately prove to be one of the most important outcomes of this research.

Traditional Treatment for Coping with Anxiety

Benzodiazepines such as alprazolam (Xanax) or diazepam (Valium) can ease anxiety, but long-term use may lead to tolerance and dependence. Stopping such medicines abruptly can trigger severe withdrawal symptoms.

Doctors also prescribe antidepressants such as SSRIs for generalized anxiety disorder. They can be very helpful for some people but are not effective for everyone. Side effects may include nausea, insomnia, fatigue and sexual difficulties. Stopping some antidepressants can also produce unpleasant withdrawal symptoms.

DT120 is a radically different model. In the Panorama trial, people were monitored for at least eight hours on treatment day. The average participant met the study’s criteria for ending the supervised session after a little more than six hours.

No, this is not a medicine you would pick up at the pharmacy, take home and swallow before breakfast.

What Were the Side Effects of LSD?

LSD is called a psychedelic for a reason. In the new study, nearly 95 percent of the people receiving the 100-microgram dose reported some type of treatment-emergent adverse event. Most were mild to moderate and occurred on the day the drug was administered.

The most common reactions included:

• Illusions or altered perceptions
• Nausea
• Headache

Definium reported no drug-related serious adverse events and no signal of suicidal behavior in the Panorama trial.

But these results should not be interpreted to mean that LSD is harmless or that people should experiment on their own. The treatment was administered in a controlled clinical setting with patients monitored for hours. Screening, supervision and follow-up will be crucial questions if the FDA ultimately approves this treatment.

This Isn’t the First Positive LSD Trial

The new results did not completely surprise us. Research published in JAMA (Oct. 21, 2025) described a clinical trial involving nearly 200 adults with moderate to severe generalized anxiety disorder (GAD). The researchers randomly assigned participants to placebo or one of four doses of pharmaceutical lysergide: 25, 50, 100 or 200 micrograms. The results showed a dose-dependent reduction in anxiety. The strongest results occurred with the higher doses.

The investigators concluded:

“In participants with moderate to severe GAD, a single dose of MM120 produced a dose-dependent reduction in anxiety.”

That Phase 2 study helped investigators select the 100-microgram dose that went forward into Phase 3 testing.

Three Phase 3 Successes Raise the Stakes

Definium has now announced three positive Phase 3 trials involving DT120. Two involved generalized anxiety disorder. Another studied major depressive disorder. That is important because depression and anxiety frequently overlap, and many of the drugs doctors currently prescribe for anxiety are actually antidepressants.

The company hopes ultimately to obtain FDA approval for DT120 for both generalized anxiety disorder and major depression. Whether the FDA will agree remains to be seen.

It is also far too early to know whether a single psychedelic treatment could replace daily medication for substantial numbers of people. The Panorama study includes a longer open-label extension in which qualifying patients may receive additional doses if symptoms warrant them.

So we are not ready to call this literally “one and done.” But a treatment that provides meaningful relief for 12 weeks after a single administration represents a profoundly different approach to treating chronic anxiety.

My Personal History With LSD Research

At this point I need to disclose something unusual about my own background. First, I have never personally taken LSD, psilocybin or any other psychedelic drug.

I was a researcher, not an evangelist for hallucinogens. From 1967 to 1969, I worked in the Neuropharmacology Laboratory at the New Jersey Neuropsychiatric Institute. My mentors were Dr. Carl Pfeiffer and Dr. Leonide Goldstein.

Both were actively involved in basic research on psychedelic compounds such as LSD and psilocybin. Dr. Pfeiffer’s work on the subject goes back at least to a paper published on March 14, 1957, in the Annals of the New York Academy of Sciences.

My research involved testing hallucinogenic compounds in rabbits and rats using quantitative EEG technology that Dr. Goldstein had brought to the United States from France. One of our papers was published in the Proceedings of the National Academy of Sciences (October 1969).

I mention this history for transparency, but also because watching psychedelic research disappear and then reappear more than half a century later has been extraordinary.

How LSD Research Went From Science to Taboo

Swiss chemist Albert Hofmann first synthesized LSD in 1938 while working with compounds derived from ergot fungus. He discovered its remarkable psychological effects in 1943. During the 1950s and 1960s, scientists investigated LSD and other psychedelic drugs for a variety of psychiatric problems.

Then everything changed. Psychedelic drugs became deeply associated with the counterculture of the late 1960s. In 1970, Congress passed the Controlled Substances Act. LSD was classified as a Schedule I controlled substance, a category defined as having no currently accepted medical use and a high potential for abuse.

For researchers, the door nearly slammed shut. Obtaining approval and funding for human psychedelic research became extremely difficult.

Half a century later, that door has reopened. Scientists are now investigating psychedelics for depression, anxiety, post-traumatic stress disorder and other psychiatric conditions. Seeing an LSD formulation advance through successful Phase 3 clinical trials would have been almost unimaginable when psychedelic research collapsed in the early 1970s.

Meditation vs. Medication

LSD is certainly not the only alternative to long-term anti-anxiety medication. A randomized controlled trial published in JAMA Psychiatry (Nov. 9, 2022) compared mindfulness-based stress reduction with the antidepressant escitalopram (Lexapro) for anxiety disorders.

The study included more than 200 people and compared mindfulness-based stress reduction to escitalopram. Trial volunteers took the medication or attended mindfulness training sessions and practiced at home for eight weeks.

Results of the Trial:

By the end of that time, people in both groups were measurably less anxious. (To assess this, the investigators used a standardized tool called the Global Clinical Impression of Severity scale.) During the trial, 8 percent of those in the medication group dropped out due to side effects. More than three-fourths of those taking escitalopram reported reactions such as trouble sleeping, nausea, fatigue, headache, daytime drowsiness or sexual difficulties.

No one dropped out of the mindfulness group, although about a tenth of them felt more anxious at some point during the trial. The bottom line: Mindfulness worked as well against anxiety disorders as medication, without the complications. Psychiatrists commenting on the article pointed out, though, that the practice of mindfulness required time. Many anxious people may not feel they have the time they need to meditate or complete the daily 45-minute home practice.

What Do People Say About Psychedelics for Coping with Anxiety or Depression?

Our readers have expressed very different views about psychedelic drugs.

Diane wrote:

“I wouldn’t hesitate to take Psilocybin or LSD if I were very depressed.”

Jan described experimenting with LSD and psilocybin decades ago:

She hopes research continues because she believes psychedelics could have potential for treating depression and anxiety.

Another reader, who asked to remain anonymous, recalled taking LSD when younger and described the experiences as positive.

But not everyone shares that enthusiasm.

GRD offered a starkly different perspective:

“As a young woman a psychiatrist gave me LSD & it almost ruined my life! BEWARE & do your homework!”

Michael, who has suffered from cluster headaches for many years, told us that he has used psilocybin in an effort to reduce his attacks. His experience underscores another reason psychedelic drugs have attracted renewed scientific attention, although self-treatment with illegal or unregulated psychedelics is very different from receiving a standardized drug under medical supervision.

These sharply contrasting experiences are a reminder that psychedelics are not ordinary medicines. A treatment that one person describes as profoundly beneficial may be frightening or harmful for someone else.

That makes the controlled clinical trials of pharmaceutical LSD especially important.

The People’s Pharmacy Bottom Line

We are not suggesting that anyone seek out LSD or experiment with psychedelic drugs on their own. The formulation being studied by Definium is a standardized pharmaceutical product administered in controlled clinical trials with screening and prolonged supervision by trained clinicians. It has not yet been approved by the FDA.

There are also unanswered questions. How long will the benefits last beyond three months? Who is most likely to respond? Who should never receive LSD? How often might some people need another treatment? What psychological support should accompany a psychedelic session? And what uncommon complications might become apparent when thousands rather than hundreds of people are treated?

Those questions matter!

But after watching LSD research essentially disappear for half a century, I find the current development remarkable. A drug that became one of the great symbols of 1960s counterculture may someday become a prescription treatment for some of the most common psychiatric disorders in America.

Science sometimes takes very unexpected turns.

Learn More About Coping with Anxiety

For more information about non-drug approaches, you may want to listen to:

Show 1262: How to Manage Your Anxiety

And this earlier program now seems especially relevant:

Show 1188: The Healing Potential of Psychedelic Drugs—LSD Without Hallucinations?

What Do You Think?

Now we would really like to hear from you. If the FDA eventually approves a pharmaceutical form of LSD for generalized anxiety disorder or depression, would you consider a medically supervised treatment?

Have you ever had an experience with LSD, psilocybin or another psychedelic, either positive or negative? Have conventional treatments for anxiety or depression worked well for you? Did you have trouble stopping benzodiazepines or antidepressants?

Please share your story in the comment section below. Just click on the green box that says “View Comments.”